ANRO Stock Analysis: Buy, Sell, or Hold?
ANRO - Alto Neuroscience Inc.
$23.41
0.93 (4.14%)
▲
5d:
+13.26%
30d:
+16.41%
90d:
+30.49%
BUY
MODERATE Confidence
Analysis Updated: Apr 1, 2026 12:00 AM ET
Earnings: May 13, 2026
Smart Money Accumulation
ANRO is down 8.2% this week, but smart money is accumulating calls. Top strike: $22.5 2026-05-15 with 43 OI. Call ratio: 100% View Scanner →
Strength: 9.1/10
Get Alerted When ANRO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ANRO shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: ANRO shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: ANRO is currently trading at $23.41, which is considered extended relative to its 30-day fair value range of $19.67 to $22.49.
Technical Outlook: Technically, ANRO is in a strong uptrend. The price is approaching resistance at $23.80. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.1% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (5th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $36.00 (+53.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ANRO is in a strong uptrend. The price is approaching resistance at $23.80. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.1% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (5th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $36.00 (+53.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$19.67 -
$22.49
Company Quality Score
58/100
(HOLD)
Options IV Signal
5th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
65.4%
All Signals
- BEARISH: Price extended above range
- BULLISH: Options cheap (IV 5th percentile)
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.1%)
- BULLISH: Trading 53.8% below Wall St target ($36.00)
Fair Price Analysis
30-Day Fair Range
$19.67 -
$22.49
Current vs Fair Value
EXTENDED
Expected Move (7 Days)
±$4.14
(17.7%)
Support & Resistance Levels
Support Level
$19.41
Resistance Level
$23.80
Current Trend
Strong Uptrend
Technical data as of
Apr 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-11.73
Wall Street Target
$36.00
(+53.8%)
Share & Embed Analysis
Last updated: April 02, 2026 5:56 AM ET
Data refreshes hourly during market hours. Next update: 6:56 AM
Data refreshes hourly during market hours. Next update: 6:56 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ANRO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$25 | 56 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$411 | 52 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$111 | 57 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$8 | 52 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$33 | 61 BUY |
